Research programme: pegylated cancer therapeutics - Polaris Pharmaceuticals

Drug Profile

Research programme: pegylated cancer therapeutics - Polaris Pharmaceuticals

Alternative Names: Histidase-PEG 20; PEG-histidase; PEG-TNF - Phoenix Pharmacologics; PEG-TNFα; PEGylated TNF - Phoenix Pharmacologics; TNF-PEG 20

Latest Information Update: 16 Sep 2016

Price : $50

At a glance

  • Originator Phoenix Pharmacologics
  • Developer Polaris Pharmaceuticals
  • Class Blood proteins; Enzymes; Glycoproteins; Monokines; Polyethylene glycols; Tumour necrosis factors
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Sep 2016 Pegylated TNF is still in preclinical trials for Cancer in USA (Polaris pipeline; September 2016)
  • 24 May 2010 Preclinical development is ongoing in USA
  • 22 Apr 2009 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top